IP Library Granted Patent US 7,151,085
Granted Patent B2
US 7,151,085 · App. 10/990,055 · Granted Dec 19, 2006

Therapeutic methods using cyclosporine components

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,151,085
App. No.
10/990,055
Granted
Dec 19, 2006
Kind
B2
Abstract

Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporinee component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.

Claims (9)

1. A method of treating a mucin deficiency of oral mucosal tissue in a human or animal, the method comprising:

Topically administering a therapeutically effective amount of a cyclosporinee component selected from the group consisting of cyclosporin A, salts thereof and mixtures thereof, to a mucosal tissue in an oral cavity of a human or animal having a mucin deficiency, thereby treating the mucin deficiency.

2. The method of claim 1 wherein the human or animal has dry mouth syndrome resulting at least in part from the mucin deficiency, and the administering step is effective in treating the dry mouth syndrome.

3. The method of claim 1 wherein the mucin deficiency at least in part results in the human or animal having a condition selected from the group consisting of oral submucous fibrosis, oral nevi, and cancers of the oral mucosa.

4. The method of claim 1 wherein the cyclosporinee component is cyclosporinee A.

5. The method of claim 1 wherein the cyclosporinee component is administered in an oral rinse.

6. The method of claim 1 wherein the cyclosporinee component is administered in an emulsion.

7. The method of claim 5 wherein the oral rinse includes about 0.03% to about 15% by weight of the cyclosporinee component.

8. The method of claim 6 wherein the oral rinse includes about 0.1% to about 5% by weight of the cyclosporinee component.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2017
From: ALLERGAN, INC.
To: SAINT REGIS MOHAWK TRIBE
Reel/Frame 043830/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2004
From: STERN, MICHAEL E.; POWER, DAVID
To: ALLERGAN, INC.
Reel/Frame 016008/0971 →